Logo image of CPRX

CATALYST PHARMACEUTICALS INC (CPRX) Stock Fundamental Analysis

USA - NASDAQ:CPRX - US14888U1016 - Common Stock

19.78 USD
-0.62 (-3.04%)
Last: 9/19/2025, 8:00:00 PM
19.79 USD
+0.01 (+0.05%)
After Hours: 9/19/2025, 8:00:00 PM
Fundamental Rating

8

We assign a fundamental rating of 8 out of 10 to CPRX. CPRX was compared to 540 industry peers in the Biotechnology industry. CPRX scores excellent points on both the profitability and health parts. This is a solid base for a good stock. CPRX is evaluated to be cheap and growing strongly. This does not happen too often! This makes CPRX very considerable for value and growth and quality investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

9

1. Profitability

1.1 Basic Checks

In the past year CPRX was profitable.
CPRX had a positive operating cash flow in the past year.
Each year in the past 5 years CPRX has been profitable.
CPRX had a positive operating cash flow in each of the past 5 years.
CPRX Yearly Net Income VS EBIT VS OCF VS FCFCPRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M

1.2 Ratios

Looking at the Return On Assets, with a value of 21.47%, CPRX belongs to the top of the industry, outperforming 96.85% of the companies in the same industry.
The Return On Equity of CPRX (24.38%) is better than 96.48% of its industry peers.
The Return On Invested Capital of CPRX (21.45%) is better than 97.59% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for CPRX is above the industry average of 15.95%.
The last Return On Invested Capital (21.45%) for CPRX is above the 3 year average (20.37%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 21.47%
ROE 24.38%
ROIC 21.45%
ROA(3y)18.85%
ROA(5y)22.43%
ROE(3y)22.87%
ROE(5y)26.38%
ROIC(3y)20.37%
ROIC(5y)19.67%
CPRX Yearly ROA, ROE, ROICCPRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 -60

1.3 Margins

The Profit Margin of CPRX (37.36%) is better than 97.41% of its industry peers.
In the last couple of years the Profit Margin of CPRX has remained more or less at the same level.
The Operating Margin of CPRX (43.58%) is better than 99.07% of its industry peers.
In the last couple of years the Operating Margin of CPRX has grown nicely.
CPRX's Gross Margin of 85.78% is amongst the best of the industry. CPRX outperforms 88.52% of its industry peers.
In the last couple of years the Gross Margin of CPRX has remained more or less at the same level.
Industry RankSector Rank
OM 43.58%
PM (TTM) 37.36%
GM 85.78%
OM growth 3Y2.16%
OM growth 5Y5%
PM growth 3Y5.91%
PM growth 5Y1.34%
GM growth 3Y0.61%
GM growth 5Y0.11%
CPRX Yearly Profit, Operating, Gross MarginsCPRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

More info and screens

8

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so CPRX is creating value.
CPRX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for CPRX has been increased compared to 5 years ago.
CPRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CPRX Yearly Shares OutstandingCPRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
CPRX Yearly Total Debt VS Total AssetsCPRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

CPRX has an Altman-Z score of 15.69. This indicates that CPRX is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of CPRX (15.69) is better than 89.63% of its industry peers.
There is no outstanding debt for CPRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 15.69
ROIC/WACC2.23
WACC9.63%
CPRX Yearly LT Debt VS Equity VS FCFCPRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

CPRX has a Current Ratio of 6.71. This indicates that CPRX is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 6.71, CPRX is doing good in the industry, outperforming 67.22% of the companies in the same industry.
CPRX has a Quick Ratio of 6.55. This indicates that CPRX is financially healthy and has no problem in meeting its short term obligations.
CPRX's Quick ratio of 6.55 is fine compared to the rest of the industry. CPRX outperforms 66.67% of its industry peers.
Industry RankSector Rank
Current Ratio 6.71
Quick Ratio 6.55
CPRX Yearly Current Assets VS Current LiabilitesCPRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

9

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 205.56% over the past year.
CPRX shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 34.29% yearly.
The Revenue has grown by 28.54% in the past year. This is a very strong growth!
Measured over the past years, CPRX shows a very strong growth in Revenue. The Revenue has been growing by 36.89% on average per year.
EPS 1Y (TTM)205.56%
EPS 3Y52.41%
EPS 5Y34.29%
EPS Q2Q%24.24%
Revenue 1Y (TTM)28.54%
Revenue growth 3Y51.72%
Revenue growth 5Y36.89%
Sales Q2Q%19.44%

3.2 Future

The Earnings Per Share is expected to grow by 26.50% on average over the next years. This is a very strong growth
CPRX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.27% yearly.
EPS Next Y13.37%
EPS Next 2Y15.59%
EPS Next 3Y12.05%
EPS Next 5Y26.5%
Revenue Next Year16.03%
Revenue Next 2Y12.76%
Revenue Next 3Y11.61%
Revenue Next 5Y11.27%

3.3 Evolution

The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
CPRX Yearly Revenue VS EstimatesCPRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
CPRX Yearly EPS VS EstimatesCPRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 1 2 3 4 5

More info and screens

9

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 11.99 indicates a reasonable valuation of CPRX.
CPRX's Price/Earnings ratio is rather cheap when compared to the industry. CPRX is cheaper than 96.67% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 27.38. CPRX is valued rather cheaply when compared to this.
The Price/Forward Earnings ratio is 11.30, which indicates a very decent valuation of CPRX.
Based on the Price/Forward Earnings ratio, CPRX is valued cheaper than 96.67% of the companies in the same industry.
CPRX's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.86.
Industry RankSector Rank
PE 11.99
Fwd PE 11.3
CPRX Price Earnings VS Forward Price EarningsCPRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

97.78% of the companies in the same industry are more expensive than CPRX, based on the Enterprise Value to EBITDA ratio.
98.52% of the companies in the same industry are more expensive than CPRX, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 8.81
EV/EBITDA 6.56
CPRX Per share dataCPRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of CPRX may justify a higher PE ratio.
CPRX's earnings are expected to grow with 12.05% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.9
PEG (5Y)0.35
EPS Next 2Y15.59%
EPS Next 3Y12.05%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CPRX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CATALYST PHARMACEUTICALS INC

NASDAQ:CPRX (9/19/2025, 8:00:00 PM)

After market: 19.79 +0.01 (+0.05%)

19.78

-0.62 (-3.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06 2025-08-06/amc
Earnings (Next)11-04 2025-11-04/amc
Inst Owners83.35%
Inst Owner Change2%
Ins Owners5.41%
Ins Owner Change1.17%
Market Cap2.42B
Analysts88.57
Price Target34.68 (75.33%)
Short Float %6.93%
Short Ratio5.34
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.95%
Min EPS beat(2)4.13%
Max EPS beat(2)29.76%
EPS beat(4)4
Avg EPS beat(4)18.54%
Min EPS beat(4)4.13%
Max EPS beat(4)29.76%
EPS beat(8)8
Avg EPS beat(8)15.48%
EPS beat(12)11
Avg EPS beat(12)12.83%
EPS beat(16)12
Avg EPS beat(16)7.88%
Revenue beat(2)2
Avg Revenue beat(2)3.81%
Min Revenue beat(2)2.19%
Max Revenue beat(2)5.44%
Revenue beat(4)4
Avg Revenue beat(4)3.37%
Min Revenue beat(4)2.19%
Max Revenue beat(4)5.44%
Revenue beat(8)7
Avg Revenue beat(8)2.76%
Revenue beat(12)11
Avg Revenue beat(12)3.19%
Revenue beat(16)13
Avg Revenue beat(16)2.7%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-1.98%
EPS NQ rev (3m)-4.35%
EPS NY rev (1m)-0.27%
EPS NY rev (3m)-0.27%
Revenue NQ rev (1m)-0.19%
Revenue NQ rev (3m)-1.29%
Revenue NY rev (1m)0.12%
Revenue NY rev (3m)0.12%
Valuation
Industry RankSector Rank
PE 11.99
Fwd PE 11.3
P/S 4.33
P/FCF 8.81
P/OCF 8.8
P/B 2.83
P/tB 3.37
EV/EBITDA 6.56
EPS(TTM)1.65
EY8.34%
EPS(NY)1.75
Fwd EY8.85%
FCF(TTM)2.24
FCFY11.35%
OCF(TTM)2.25
OCFY11.36%
SpS4.56
BVpS6.99
TBVpS5.87
PEG (NY)0.9
PEG (5Y)0.35
Profitability
Industry RankSector Rank
ROA 21.47%
ROE 24.38%
ROCE 28.34%
ROIC 21.45%
ROICexc 89.37%
ROICexgc 270.38%
OM 43.58%
PM (TTM) 37.36%
GM 85.78%
FCFM 49.19%
ROA(3y)18.85%
ROA(5y)22.43%
ROE(3y)22.87%
ROE(5y)26.38%
ROIC(3y)20.37%
ROIC(5y)19.67%
ROICexc(3y)162.63%
ROICexc(5y)159.51%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)26.92%
ROCE(5y)25.99%
ROICexcg growth 3Y8.72%
ROICexcg growth 5YN/A
ROICexc growth 3Y-30.16%
ROICexc growth 5YN/A
OM growth 3Y2.16%
OM growth 5Y5%
PM growth 3Y5.91%
PM growth 5Y1.34%
GM growth 3Y0.61%
GM growth 5Y0.11%
F-Score6
Asset Turnover0.57
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 0.99%
Cap/Sales 0.07%
Interest Coverage 165.59
Cash Conversion 97.81%
Profit Quality 131.65%
Current Ratio 6.71
Quick Ratio 6.55
Altman-Z 15.69
F-Score6
WACC9.63%
ROIC/WACC2.23
Cap/Depr(3y)0.72%
Cap/Depr(5y)100.44%
Cap/Sales(3y)0.06%
Cap/Sales(5y)0.18%
Profit Quality(3y)162.12%
Profit Quality(5y)139.35%
High Growth Momentum
Growth
EPS 1Y (TTM)205.56%
EPS 3Y52.41%
EPS 5Y34.29%
EPS Q2Q%24.24%
EPS Next Y13.37%
EPS Next 2Y15.59%
EPS Next 3Y12.05%
EPS Next 5Y26.5%
Revenue 1Y (TTM)28.54%
Revenue growth 3Y51.72%
Revenue growth 5Y36.89%
Sales Q2Q%19.44%
Revenue Next Year16.03%
Revenue Next 2Y12.76%
Revenue Next 3Y11.61%
Revenue Next 5Y11.27%
EBIT growth 1Y183.49%
EBIT growth 3Y55%
EBIT growth 5Y43.74%
EBIT Next Year24.8%
EBIT Next 3Y19.23%
EBIT Next 5YN/A
FCF growth 1Y121.55%
FCF growth 3Y59.11%
FCF growth 5Y47.22%
OCF growth 1Y121.67%
OCF growth 3Y58.35%
OCF growth 5Y47.28%